Cytokine Therapy With Interleukin-2/Anti–Interleukin-2 Monoclonal Antibody Complexes Expands CD4+CD25+Foxp3+ Regulatory T Cells and Attenuates Development and Progression of Atherosclerosis | Zendy

Tam Nguyen Dinh | Zendy; Tin Kyaw | Zendy; Peter Kanellakis | Zendy; Kelly To | Zendy; Peter G. Tipping | Zendy; BanHock Toh | Zendy; A. Bobik | Zendy; Alex Agrotis | Zendy

Open Access

Cytokine Therapy With Interleukin-2/Anti–Interleukin-2 Monoclonal Antibody Complexes Expands CD4+CD25+Foxp3+ Regulatory T Cells and Attenuates Development and Progression of Atherosclerosis

Author(s) -

Tam Nguyen Dinh,

Tin Kyaw,

Peter Kanellakis,

Kelly To,

Peter G. Tipping,

BanHock Toh,

A. Bobik,

Alex Agrotis

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.099044

Subject(s) - foxp3 , il 2 receptor , medicine , immunology , cytokine , adoptive cell transfer , interleukin , t cell , immune system

CD4+CD25+Foxp3+ regulatory T cells (Tregs) attenuate atherosclerosis, but their therapeutic application by adoptive transfer is limited by the need for their expansion in vitro and limited purity. Recently, an interleukin (IL)-2/anti-IL-2 neutralizing monoclonal antibody (IL-2/anti-IL-2 mAb) complex has been shown to expand these Tregs. We examined the capacity of a modified IL-2/anti-IL-2 mAb treatment to expand Tregs and inhibit both the progression and development of developed atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research